

Proton Pump Inhibitors: Use In Pediatric Patients



The Centers for Medicare & Medicaid Services (CMS), Medicaid Integrity Group (MIG) has identified issues with the utilization of medications in the proton pump inhibitor (PPI) drug therapy class. The U.S. Food and Drug Administration (FDA) approves product labeling for prescription drugs. The MIG has identified that some providers may have prescribed PPIs outside of FDA-approved product labeling for indication, age, dosage, or duration of therapy. Therefore, CMS's goal is to improve quality of care and enhance patient safety by educating providers on the proper prescribing of PPIs to pediatric patients.

This fact sheet summarizes for providers the current FDA-approved product labeling for the use of PPI medications in pediatric patients. After reading this fact sheet, providers should be able to accurately:

- Recall whether each PPI is FDA approved to treat gastroesophageal reflux disease (GERD), erosive esophagitis (EE), or both conditions in pediatric patients;
- Recall the dosing options and guidelines for each PPI that is FDA approved for pediatric patients;
- Explain why PPIs are not indicated for use in infants; and
- Describe the adverse reactions of and risks related to the use of PPIs in pediatric patients.

Overview of Proton Pump Inhibitors

PPIs block the acid-producing enzyme system in the stomach wall and prevent acid production in the stomach. Lack of acid in the stomach prevents ulcer formation; promotes healing of existing ulcers in the esophagus, stomach, and duodenum; and provides symptom relief. PPIs differ in how they are metabolized by the body, how they interact with other medications, and the length of time they are active in the body. However, there is no evidence that one PPI is more effective than another.

Defining Pediatric Patients

For the purpose of this document, the term “pediatric patients” collectively includes infants, children, and adolescents younger than 18 years old. Infants are further defined to be any patient younger than one year old.

The literature on PPIs does not have well-defined age ranges for pediatric patients. Some studies define children as patients 1 to 12 years old and adolescents as patients 13 to 17 years old. Other studies define children as patients 1 to 17 years old. The ages of the patients were also inconsistent in the clinical trials conducted for medication approval. This inconsistency is reflected in the age ranges in Figure 1.



FDA-Approved Indications for Proton Pump Inhibitors in Pediatric Patients

Medications in the PPI drug therapy class have been proven safe and effective in children and adolescents for the short-term treatment of GERD and EE. However, PPIs are often used to treat conditions that have not been formally diagnosed.

PPIs are used for the prevention and treatment of gastric acid related conditions. These FDA-approved indications and age ranges apply to the prescribing of PPIs:

- The FDA-approved indications for use in pediatric patients are the short-term treatment of symptomatic GERD and healing of EE;
- Only rabeprazole is FDA approved for the treatment of GERD in pediatric patients ages 1 to 11;
- No PPI is FDA approved for use in patients younger than one year old; and
- Five of the six currently available PPIs have an FDA-approved indication for patients younger than 18 years old.

The FDA-approved pediatric age ranges and indications for PPIs are provided in Figure 1 below. The FDA-approved pediatric indications and dosages for medications in the PPI drug therapy class are provided in the document “Proton Pump Inhibitors: U.S. Food and Drug Administration-Approved Indications and Dosages for Use in Pediatric Patients.”

Figure 1. FDA-Approved Pediatric Age Ranges and Indications for Proton Pump Inhibitors



■ symptomatic GERD
 ■ healing of EE
 ■ treatment of GERD

* Studies on the effectiveness of omeprazole (Prilosec®) were conducted in pediatric patients 1 to 16 years old.

† Studies on the effectiveness of pantoprazole (Protonix®) were conducted in pediatric patients 1 to 16 years old.



Treatment Guidelines for Children with Gastroesophageal Reflux

The North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN) developed guidelines for the treatment of GERD in pediatric patients. The guidelines are available from the Agency for Healthcare Research and Quality (AHRQ) National Guideline Clearinghouse database at <http://www.guideline.gov/content.aspx?id=24538> on the AHRQ website. The AHRQ is a branch of the U.S. Department of Health and Human Services.

For more information on the National Guideline Clearinghouse database, visit <http://www.guideline.gov> on the AHRQ website.

Clinical Trials for the Treatment of Gastroesophageal Reflux in Infants

Clinical trials for the use of PPIs in infants have been conducted with esomeprazole, lansoprazole, and pantoprazole. The results of these trials showed that PPIs are not effective in patients younger than one year old for the treatment of symptomatic GERD.

In a multicenter, randomized, double-blind, placebo-controlled, treatment-withdrawal study, 80 patients were treated with either esomeprazole or placebo. Results showed there was no statistically significant difference in the time to treatment withdrawal between the two groups.[6]


Infants treated with lansoprazole for symptoms of crying, fussing, or irritability with feedings showed no difference in the percentage of response than patients treated with placebo. This lack of efficacy does not support the use of lansoprazole in infants.[7]

Pantoprazole was studied in 129 patients (1 to 11 months old) with symptomatic GERD. This multicenter, randomized, double-blind, placebo-controlled, treatment-withdrawal study found that pantoprazole was not effective. Adverse reactions were more prevalent in the patients who were treated with pantoprazole.[8]

ACRONYMS

AHRQ	Agency for Healthcare Research and Quality
CDAD	Clostridium difficile-associated diarrhea
CDER	Center for Drug Evaluation and Research
CMS	Centers for Medicare & Medicaid Services
EE	erosive esophagitis
ESPGHAN	European Society for Pediatric Gastroenterology, Hepatology, and Nutrition
FDA	U.S. Food and Drug Administration
GERD	gastroesophageal reflux disease
MIG	Medicaid Integrity Group
NASPGHAN	North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition
OTC	over the counter
PPI	proton pump inhibitor

Adverse Reactions and Risks of the Use of Proton Pump Inhibitors in Pediatric Patients



PPIs are generally well tolerated. The most common adverse reactions seen in pediatric patients are headache, diarrhea, constipation, and nausea.[9, 10, 11, 12, 13] The use of PPIs has been associated with drug interactions and Clostridium difficile-associated diarrhea (CDAD). Hypomagnesemia has also been reported in adults.

Risk of Drug Interactions with Proton Pump Inhibitors

Clinically significant drug interactions with PPIs are rare. Chronic acid suppression can minimize the effectiveness of any medication requiring an acidic environment for absorption. Commonly prescribed medications affected by acid suppression are ampicillin esters, digoxin, atazanavir, ketoconazole, and iron salts.[14]

There is also a risk of adverse drug interactions between PPIs and other medications that are metabolized via the cytochrome P450 system. While specific interactions are not well documented, there is substantial evidence regarding an interaction between clopidogrel and omeprazole.[15] Other drug interactions that may be clinically significant are dependent on the specific cytochrome P450 enzyme substrates and the specific PPI. Search the medication name at <http://www.accessdata.fda.gov/scripts/cder/drugsatfda> on the FDA website to retrieve prescribing information and detailed drug interactions for each PPI medication.

Risk of Clostridium difficile-Associated Diarrhea

On February 8, 2012, the FDA published a Drug Safety Communication to inform patients, caregivers, and providers that PPIs may be associated with an increased risk of CDAD. Symptoms of CDAD include abdominal pain, fever, and watery stools. Patients who take a PPI and develop diarrhea that does not improve should be evaluated for CDAD. Patients with advanced age, certain chronic medical conditions, and those taking broad spectrum antibiotics are at greatest risk for developing CDAD. The FDA recommends using the lowest dose and shortest duration of PPI therapy possible and recommends advising patients to seek medical attention if they develop symptoms of CDAD.[16] The FDA requires that a Medication Guide be dispensed with every new or refilled PPI prescription. The Medication Guide informs patients, caregivers, and providers about the risk of CDAD when taking a PPI. Links to the Medication Guides can be found at <http://www.fda.gov/Drugs/DrugSafety/ucm085729.htm> on the FDA website.

Risk of Hypomagnesemia

In March 2011, the FDA published a Drug Safety Communication to inform consumers and health professionals that the long-term use of PPIs may cause hypomagnesemia. In 25 percent of patients, magnesium supplementation was not sufficient to correct PPI-induced hypomagnesemia; rather, PPI therapy had to be discontinued. The deficiency did not appear to be dose-related and reappeared after rechallenge with a PPI. The FDA recommends obtaining a serum magnesium level prior to initiation of therapy if a patient is to be on prolonged treatment.[17]

Resources

Please visit <http://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-State/By-State.html> for links to State Medicaid program websites.

The Center for Drug Evaluation and Research (CDER) hosts a website providing health professionals with current information on over-the-counter (OTC) and prescription drugs. Visit <http://www.fda.gov/Drugs/ResourcesForYou/HealthProfessionals> to access drug-related databases, information on drug recalls and alerts, current information on new and generic drug approvals, and information on drug safety and availability.

Section 1927(g)(1)(B) of the Social Security Act identifies the predetermined standards that the State's drug use review program must use to assess data on drug use. Visit http://www.ssa.gov/OP_Home/ssact/title19/1927.htm for information on the compendia.



References

- 1 Nexium® (esomeprazole) prescribing information. (2011, June). Retrieved July 26, 2011, from http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022101s007,021153s038,021957s010lbl.pdf
- 2 Prevacid® (lansoprazole) prescribing information. (2011, June). Retrieved July 22, 2011, from http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020406s075,021428s022lbl.pdf
- 3 Prilosec® (omeprazole) prescribing information. (2011, June). Retrieved July 22, 2011, from http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022056s007,019810s091lbl.pdf
- 4 Protonix® (pantoprazole) prescribing information. (2011, May 20). Retrieved June 23, 2011, from http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020987s041,022020s005lbl.pdf
- 5 Aciphex® (rabeprazole) prescribing information. (2011, May). Retrieved June 23, 2011, from http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020973s028lbl.pdf
- 6 Nexium® (esomeprazole) prescribing information. (2011, June). Retrieved July 26, 2011, from http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022101s007,021153s038,021957s010lbl.pdf
- 7 Prevacid® (lansoprazole) prescribing information. (2011, June). Retrieved July 22, 2011, from http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020406s075,021428s022lbl.pdf
- 8 Protonix® (pantoprazole) prescribing information. (2011, May 20). Retrieved June 23, 2011, from http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020987s041,022020s005lbl.pdf
- 9 Nexium® (esomeprazole) prescribing information. (2011, June). Retrieved July 26, 2011, from http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022101s007,021153s038,021957s010lbl.pdf
- 10 Prevacid® (lansoprazole) prescribing information. (2011, June). Retrieved July 22, 2011, from http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020406s075,021428s022lbl.pdf
- 11 Prilosec® (omeprazole) prescribing information. (2011, June). Retrieved July 22, 2011, from http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022056s007,019810s091lbl.pdf
- 12 Protonix® (pantoprazole) prescribing information. (2011, May 20). Retrieved June 23, 2011, from http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020987s041,022020s005lbl.pdf
- 13 Aciphex® (rabeprazole) prescribing information. (2013, March 26). Retrieved June 23, 2011, from http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204736s000lbl.pdf
- 14 Dexilant™ (dexlansoprazole) prescribing information. (2011, June). Retrieved July 26, 2011, from http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022287s008lbl.pdf
- 15 Prilosec® (omeprazole) prescribing information. (2011, June). Retrieved July 22, 2011, from http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022056s007,019810s091lbl.pdf
- 16 U.S. Department of Health and Human Services. U.S. Food and Drug Administration. (2012, February 8). FDA Drug Safety Communication: Clostridium difficile-Associated Diarrhea Can Be Associated with Stomach Acid Drugs Known as Proton Pump Inhibitors (PPIs). [FDA Safety Communication]. Retrieved February 8, 2012, from <http://www.fda.gov/Drugs/DrugSafety/ucm290510.htm>
- 17 U.S. Department of Health and Human Services. U.S. Food and Drug Administration. (2011, March 2). FDA Drug Safety Communication: Low Magnesium Levels Can Be Associated with Long-Term Use of Proton Pump Inhibitor Drugs (PPIs). [FDA Drug Safety Communication]. Retrieved June 13, 2011, from <http://www.fda.gov/Drugs/DrugSafety/ucm245011.htm>



Disclaimer

This fact sheet was current at the time it was published or uploaded onto the web. Medicaid and Medicare policies change frequently, so links to the source documents have been provided within the document for your reference.

This fact sheet was prepared as a service to the public and is not intended to grant rights or impose obligations. This fact sheet may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. Use of this material is voluntary. Inclusion of a link does not constitute CMS endorsement of the material. We encourage readers to review the specific statutes, regulations, and other interpretive materials for a full and accurate statement of their contents.

August 2013

This fact sheet was prepared by the Education Medicaid Integrity Contractor for the CMS Medicaid Integrity Program (MIP). For more information on the MIP, please visit <http://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Pharmacy-Education-Materials/pharmacy-ed-materials.html> on the CMS website or scan the Quick Response (QR) code on the right with your mobile device.

